Welcome to our dedicated page for Crescent Cap Bdc SEC filings (Ticker: FCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crescent Cap Bdc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crescent Cap Bdc's regulatory disclosures and financial reporting.
Crescent Capital BDC, Inc. submitted a voluntary withdrawal of its 5.00% Notes due 2026 from listing and registration on the New York Stock Exchange.
The filing states the Exchange and the issuer have each complied with the relevant rules governing voluntary withdrawal under Section 12(b).
Crescent Capital BDC, Inc. submitted a voluntary withdrawal of its 5.00% Notes due 2026 from listing and registration on the New York Stock Exchange.
The filing states the Exchange and the issuer have each complied with the relevant rules governing voluntary withdrawal under Section 12(b).
Crescent Capital BDC, Inc. president and director Henry Chung reported an open‑market purchase of 4,500 shares of common stock at $11.45 per share on May 21, 2026. Following this transaction, he directly holds 20,722 shares, including 945 shares acquired through dividend reinvestment in 2026.
Crescent Capital BDC, Inc. president and director Henry Chung reported an open‑market purchase of 4,500 shares of common stock at $11.45 per share on May 21, 2026. Following this transaction, he directly holds 20,722 shares, including 945 shares acquired through dividend reinvestment in 2026.
Crescent Capital BDC, Inc. Chief Executive Officer Jason Breaux bought additional company stock in an open-market transaction. On May 20, 2026, he purchased 5,000 shares of Common Stock at $11.19 per share. Following this purchase, his direct holdings increased to 52,636 shares of Crescent Capital BDC, Inc. Common Stock.
Crescent Capital BDC, Inc. Chief Executive Officer Jason Breaux bought additional company stock in an open-market transaction. On May 20, 2026, he purchased 5,000 shares of Common Stock at $11.19 per share. Following this purchase, his direct holdings increased to 52,636 shares of Crescent Capital BDC, Inc. Common Stock.
Crescent Capital BDC, Inc. Chief Financial Officer Gerhard Lombard bought 1,000 shares of common stock in an open-market purchase at $11.12 per share on 2026-05-18. This is a direct ownership transaction.
After this trade, Lombard directly owns 37,373 common shares. This figure includes 2,088 shares acquired through dividend reinvestment in 2026, which were not previously reported under Rule 16a-11.
Crescent Capital BDC, Inc. Chief Financial Officer Gerhard Lombard bought 1,000 shares of common stock in an open-market purchase at $11.12 per share on 2026-05-18. This is a direct ownership transaction.
After this trade, Lombard directly owns 37,373 common shares. This figure includes 2,088 shares acquired through dividend reinvestment in 2026, which were not previously reported under Rule 16a-11.
Crescent Capital BDC, Inc. held its 2026 annual stockholder meeting, where 36,969,285 common shares were entitled to vote as of March 18, 2026. Stockholders elected Susan Yun Lee and Michael S. Segal as Class II directors to terms running through the 2029 annual meeting. Lee received 17,107,252 votes for, 306,098 against, and 107,901 abstentions. Segal received 16,302,024 votes for, 1,113,132 against, and 106,095 abstentions. Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 26,529,354 votes for, 211,437 against, and 155,426 abstentions.
Crescent Capital BDC, Inc. held its 2026 annual stockholder meeting, where 36,969,285 common shares were entitled to vote as of March 18, 2026. Stockholders elected Susan Yun Lee and Michael S. Segal as Class II directors to terms running through the 2029 annual meeting. Lee received 17,107,252 votes for, 306,098 against, and 107,901 abstentions. Segal received 16,302,024 votes for, 1,113,132 against, and 106,095 abstentions. Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 26,529,354 votes for, 211,437 against, and 155,426 abstentions.
Crescent Capital BDC, Inc. reported first quarter 2026 net investment income of $0.42 per share and a net loss of $0.42 per share, reflecting realized and unrealized losses on investments. Net asset value per share declined to $18.27 from $19.10 at year-end 2025.
The Board declared a regular second quarter 2026 cash dividend of $0.34 per share and special cash dividends totaling $0.09 per share, payable in three $0.03 installments. After quarter-end, the company reduced its base management fee to 1.00% and incentive fee to 15.0%, aiming to better align economics with shareholders.
Crescent Capital BDC, Inc. reported first quarter 2026 net investment income of $0.42 per share and a net loss of $0.42 per share, reflecting realized and unrealized losses on investments. Net asset value per share declined to $18.27 from $19.10 at year-end 2025.
The Board declared a regular second quarter 2026 cash dividend of $0.34 per share and special cash dividends totaling $0.09 per share, payable in three $0.03 installments. After quarter-end, the company reduced its base management fee to 1.00% and incentive fee to 15.0%, aiming to better align economics with shareholders.
CCAP’s quarterly report details an extensive portfolio of mainly floating-rate private credit investments. The holdings are concentrated in United States debt investments, with numerous unitranche first lien and senior secured first lien term loans, revolvers, and delayed draw term loans across software, health care, commercial services, and other sectors.
Many loans are priced at spreads such as S + 450 to S + 775, with stated cash interest rates often between about 8% and 12%, sometimes including additional PIK components. Maturities and revolver commitment expirations generally fall between 2026 and 2033, indicating a predominantly medium- to long-dated credit book with some international exposure in Europe, Canada, and Australia and a mix of common and preferred equity positions.
CCAP’s quarterly report details an extensive portfolio of mainly floating-rate private credit investments. The holdings are concentrated in United States debt investments, with numerous unitranche first lien and senior secured first lien term loans, revolvers, and delayed draw term loans across software, health care, commercial services, and other sectors.
Many loans are priced at spreads such as S + 450 to S + 775, with stated cash interest rates often between about 8% and 12%, sometimes including additional PIK components. Maturities and revolver commitment expirations generally fall between 2026 and 2033, indicating a predominantly medium- to long-dated credit book with some international exposure in Europe, Canada, and Australia and a mix of common and preferred equity positions.
Crescent Capital BDC, Inc. reported board changes. Effective May 5, 2026, the board accepted the resignation of Class III director Elizabeth Ko, who stated her decision was not due to any disagreement with management, the board, or company operations.
Effective May 7, 2026, the board elected Chief Executive Officer Jason Breaux and President Henry Chung as Class III directors, whose terms run until the 2027 annual meeting or until successors are elected and qualified. Breaux will serve as Chairman of the Board. Neither Breaux nor Chung will receive compensation or equity awards for board service, and both will continue in their existing executive roles.
Crescent Capital BDC, Inc. reported board changes. Effective May 5, 2026, the board accepted the resignation of Class III director Elizabeth Ko, who stated her decision was not due to any disagreement with management, the board, or company operations.
Effective May 7, 2026, the board elected Chief Executive Officer Jason Breaux and President Henry Chung as Class III directors, whose terms run until the 2027 annual meeting or until successors are elected and qualified. Breaux will serve as Chairman of the Board. Neither Breaux nor Chung will receive compensation or equity awards for board service, and both will continue in their existing executive roles.
Crescent Capital BDC, Inc. is calling a fully virtual 2026 annual stockholders meeting on May 15, 2026, at 10:00 a.m. Pacific Time. Stockholders will vote on electing Class II directors Susan Yun Lee and Michael S. Segal to terms running to the 2029 meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is March 18, 2026, when 36,969,285 common shares were outstanding, with one vote per share. The Board and all independent directors unanimously recommend voting FOR both director nominees and FOR ratification of E&Y. The proxy also outlines governance structure, committee responsibilities, related-party advisory and administration agreements, and the external management fee and incentive fee arrangements with Crescent Cap Advisors, LLC.
Crescent Capital BDC, Inc. is calling a fully virtual 2026 annual stockholders meeting on May 15, 2026, at 10:00 a.m. Pacific Time. Stockholders will vote on electing Class II directors Susan Yun Lee and Michael S. Segal to terms running to the 2029 meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is March 18, 2026, when 36,969,285 common shares were outstanding, with one vote per share. The Board and all independent directors unanimously recommend voting FOR both director nominees and FOR ratification of E&Y. The proxy also outlines governance structure, committee responsibilities, related-party advisory and administration agreements, and the external management fee and incentive fee arrangements with Crescent Cap Advisors, LLC.
Crescent Capital BDC, Inc. has issued two new series of senior unsecured notes and arranged a third under a note purchase supplement. The supplement covers up to $67.5 million of Tranche A notes due February 13, 2029, $67.5 million of Tranche B notes due February 13, 2031, and $50.0 million of Tranche C notes due May 22, 2029.
The Tranche A notes carry a fixed rate of 5.87% and the Tranche B notes a fixed rate of 6.20%. The Tranche A and Tranche B notes were issued on February 13, 2026, while issuance of the Tranche C notes is expected on May 22, 2026, subject to customary closing conditions.
To manage interest exposure, the company entered into interest rate swaps on each of Tranche A and Tranche B for notional amounts of $67.5 million. For Tranche A it will receive fixed 5.87% and pay three month term SOFR plus 2.5325% through February 13, 2029. For Tranche B it will receive fixed 6.20% and pay three month term SOFR plus 2.8050% through February 13, 2031.
Crescent Capital BDC, Inc. has issued two new series of senior unsecured notes and arranged a third under a note purchase supplement. The supplement covers up to $67.5 million of Tranche A notes due February 13, 2029, $67.5 million of Tranche B notes due February 13, 2031, and $50.0 million of Tranche C notes due May 22, 2029.
The Tranche A notes carry a fixed rate of 5.87% and the Tranche B notes a fixed rate of 6.20%. The Tranche A and Tranche B notes were issued on February 13, 2026, while issuance of the Tranche C notes is expected on May 22, 2026, subject to customary closing conditions.
To manage interest exposure, the company entered into interest rate swaps on each of Tranche A and Tranche B for notional amounts of $67.5 million. For Tranche A it will receive fixed 5.87% and pay three month term SOFR plus 2.5325% through February 13, 2029. For Tranche B it will receive fixed 6.20% and pay three month term SOFR plus 2.8050% through February 13, 2031.